Cost variance analysis of ACE-Inhibitors available in the Indian Pharmaceutical Market between May 2025 and July 2025
,
Abstract
Background: ACE-Inhibitors are commonly used to treat hypertension which is a chronic disorder requiring life-long treatment. There are numerous brands of ACE-Inhibitors available in the Indian pharmaceutical market. There is huge cost variation among different brands of ACE-Inhibitors hence the present study. Methods: Cost of all ACE-Inhibitors (tablets/capsules) available in India was obtained per unit from http://www.medguideindia.com between May to July 2025. For each formulation percentage price variation, mode price and cost ratio were calculated and analysed. Results: Among all ACE-Inhibitors, the highest percentage of price variation and cost ratio was seen in tablet Lisinopril 5mg of 4731.8% and 48.31% respectively, followed by tablet Enalapril maleate 5mg with price variation of 1214.28% and cost ratio of 13.14%. Furthermore, Ramipril 5mg tablet with percentage of price variation and cost ratio of 1098% and 11.98% respectively. Conclusion: There is a lot of price variation among the various brands of ACE-Inhibitors available in India. This can lead to noncompliance by the patient. The regulatory authorities should use their jurisdiction in controlling the price variation of such branded drugs.Wadagbalkar, P., et al. “Cost Variation Analysis of ACE Inhibitors in India.” International Journal of Basic and Clinical Pharmacology, vol. 6, 2017, pp. 1522–25.
Nasution, S. A. “The Use of ACE Inhibitor in Cardiovascular Disease.” Acta Medica Indonesiana, vol. 38, no. 1, Jan.–Mar. 2006, pp. 60–64.
James, Paul A., et al. “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8).” JAMA, vol. 311, no. 5, 5 Feb. 2014, pp. 507–20.
Whelton, Paul K., et al. “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Journal of the American College of Cardiology, vol. 71, no. 19, 15 May 2018, pp. e127–e248.
Williams, Bryan, et al. “2018 ESC/ESH Guidelines for the Management of Arterial Hypertension.” European Heart Journal, vol. 39, no. 33, 1 Sept. 2018, pp. 3021–104.
Kuruvilla, A., et al. “Prescription Patterns and Cost Analysis of Drugs in a Base Hospital in South India.” National Medical Journal of India, vol. 7, no. 4, 1994, pp. 167–68.
Eaddy, M. T., et al. “How Patient Cost-Sharing Trends Affect Adherence and Outcomes: A Literature Review.” P & T, vol. 37, 2012, pp. 45–55.
Deepak, K. R., and A. Geetha. “Cost Variation Analysis of Various Brands of Anticoagulants, Fibrinolytics, and Antiplatelet Drugs Currently Available in Indian Pharmaceutical Market.” National Journal of Physiology, Pharmacy and Pharmacology, vol. 9, no. 5, 2019, pp. 368–72.
Paunikar, A. P., and K. A. Bhave. “Cost Analysis of Oral Antidepressant Drugs Available in India.” National Journal of Physiology, Pharmacy and Pharmacology, vol. 5, no. 5, 2015, pp. 1–5.
Kaiser Family Foundation. “The Burden of Medical Debt: Results from the Kaiser Family Foundation/New York Times Medical Bills Survey.” KFF, 2015, www.kff.org/health-costs/report/the-burden-of-medical-debt-results-from-the-kaiser-family-foundation-new-york-times-medical-bills-survey/.
Kennedy, J., and S. Morgan. “Cost-Related Prescription Nonadherence in the United States and Canada: A System-Level Comparison Using the 2007 International Health Policy Survey in Seven Countries.” Clinical Therapeutics, vol. 31, no. 1, 2009, pp. 213–19.
Shankar, P. R., et al. “Ambiguous Pricing of Nepalese Medicines.” Journal of Institute of Medicine, vol. 28, 2006, pp. 35–38.
Gujjarlamudi, Hima Bindu, et al. “Cost Analysis of ACE Inhibitors and ARBs Used in Essential Hypertension.” Asian Journal of Pharmacy and Pharmacology, vol. 4, no. 3, 2018, pp. 275–79.
Singal, G. L., et al. “A Comparative Evaluation of Price and Quality of Some Branded versus Branded-Generic Medicines of the Same Manufacturer in India.” Indian Journal of Pharmacology, vol. 43, no. 2, 2011, pp. 131–36.
World Health Organization. “Essential Drugs and Medicines: Drug Finance.” WHO India, n.d., www.whoindia.org/EN/Section2/Section/Section160_959.html. Accessed 2 Oct. 2026.
Sakthivel, S. “Access to Essential Drugs and Medicines.” National Commission on Macroeconomics and Health, edited by P. G. Lal, Ministry of Health, 2005, pp. 185–210.
Kumar, V., et al. “A Comparison between Old and Latest Systems in DPCO.” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 2, 2014, pp. 19–20.
National Pharmaceutical Pricing Authority. Compendium of Notified Ceiling Prices of Scheduled Drugs. NPPA, 2015, www.nppaindia.nic.in/ceiling-price.
Bureau of Pharma PSUs of India. “Product List.” Jan Aushadhi, 2020, janaushadhi.gov.in/ProductList.aspx. Accessed 26 Apr. 2023.
Drugs (Prices Control) Order, 2013. National Pharmaceutical Pricing Authority, 2019, www.nppaindia.nic.in/wp-content/uploads/2018/12/DPCO2013_03082016.pdf. Accessed 16 Apr. 2023.
| Files | ||
| Issue | Vol 11 No 03 (2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| ACE-Inhibitors cost ratio mode price percentage price variation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
